Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Agios Pharmaceuticals, Inc.    AGIO

AGIOS PHARMACEUTICALS, INC.

(AGIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
45.67(c) 46.55(c) 45.96(c) 47.75(c) 47.47(c) Last
1 442 603 1 324 459 559 381 1 275 683 547 867 Volume
-0.61% +1.93% -1.27% +3.89% -0.59% Change
More quotes
Financials (USD)
Sales 2020 199 M - -
Net income 2020 -322 M - -
Net cash position 2020 308 M - -
P/E ratio 2020 -10,4x
Yield 2020 -
Sales 2021 167 M - -
Net income 2021 -375 M - -
Net cash position 2021 671 M - -
P/E ratio 2021 -8,56x
Yield 2021 -
Capitalization 3 288 M 3 288 M -
EV / Sales 2020 15,0x
EV / Sales 2021 15,7x
Nbr of Employees 536
Free-Float 88,7%
More Financials
Company
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and... 
More about the company
Notations Surperformance© of Agios Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about AGIOS PHARMACEUTICALS, INC.
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/20AGIOS PHARMACEUTICALS : Servier Group - Financial Year 2019/2020 Financial resul..
AQ
01/19C4 THERAPEUTICS' : Investigational New Drug Application for CFT7455 to Treat Blo..
MT
01/18AGIOS PHARMACEUTICALS : Presents Final Data from Phase 3 ClarIDHy Study of TIBSO..
AQ
01/17Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib..
GL
01/11AGIOS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Oth..
AQ
01/11Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Def..
GL
01/05AGIOS PHARMACEUTICALS : to Present at the 39th Annual J.P. Morgan Healthcare Con..
AQ
2020AGIOS PHARMACEUTICALS : Canaccord Adjusts Agios Pharmaceuticals' Price Target to..
MT
2020AGIOS PHARMACEUTICALS' : Oncology Business Sale to Provide Capital for Mitapivat..
MT
2020AGIOS PHARMACEUTICALS : Servier to Acquire Agios Pharmaceuticals Oncology Busine..
AQ
2020AGIOS PHARMACEUTICALS : to Focus on Developing and Commercializing Innovative Tr..
AQ
2020AGIOS PHARMACEUTICALS : RBC Capital Adjusts Price Target on Agios Pharmaceutical..
MT
2020AGIOS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financ..
AQ
2020SECTOR UPDATE : Health Care Shares Ending Lower Monday Afternoon
MT
More news
News in other languages on AGIOS PHARMACEUTICALS, INC.
01/19SERVIER : bénéfice net annuel en forte hausse, comparaison favorable
2020Servier achète la division oncologie de la biotech Agios Pharmaceuticals
2020AGIOS PHARMACEUTICALS : vend son portefeuille d'oncologie à Servier, prend 29,5%..
2017AGIOS PHARMACEUTICALS : I dati aggiornati dello studio clinico di fase I su IDHI..
2017AGIOS PHARMACEUTICALS : Les données mises à jour de l'essai de phase 1 du traite..
More news
Analyst Recommendations on AGIOS PHARMACEUTICALS, INC.
More recommendations
Chart AGIOS PHARMACEUTICALS, INC.
Duration : Period :
Agios Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AGIOS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 65,70 $
Last Close Price 47,47 $
Spread / Highest target 68,5%
Spread / Average Target 38,4%
Spread / Lowest Target 7,44%
EPS Revisions
Managers and Directors
NameTitle
Jacqualyn A. Fouse Chief Executive Officer & Director
David Paul Schenkein Executive Chairman
Jonathan Prim Biller CFO, Head-Legal & Corporate Affairs
Christopher J. Bowden Chief Medical Officer
Bruce Car Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
AGIOS PHARMACEUTICALS, INC.9.55%3 288
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148